UBS Reiterates Neutral Rating on IDEXX Laboratories, Inc. (IDXX)

Market Context

IDEXX Laboratories, Inc. operates in the Healthcare sector. The stock currently trades at $556.20 with a market capitalization of $56.5B. The stock has declined 21.1% over the past 52 weeks.

Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for IDEXX Laboratories, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for IDEXX Laboratories, Inc.

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 27, 2026	UBS	Neutral	N/A
Apr 28, 2026	UBS	Neutral	N/A
Apr 15, 2026	Citigroup	Neutral	N/A
Mar 31, 2026	Stifel	Buy	N/A
Feb 09, 2026	Piper Sandler	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View IDXX Stock Page